Matthew Foehr Sells 30,843 Shares of OmniAb (NASDAQ:OABI) Stock

OmniAb, Inc. (NASDAQ:OABI) CEO Matthew Foehr sold 30,843 shares of OmniAb stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $1.71, for a total value of $52,741.53. Following the completion of the transaction, the chief executive officer owned 4,403,277 shares of the company’s stock, valued at approximately $7,529,603.67. This trade represents a 0.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

OmniAb Stock Performance

Shares of OABI opened at $1.71 on Friday. The stock has a 50-day simple moving average of $1.88 and a 200-day simple moving average of $1.76. The stock has a market capitalization of $246.17 million, a PE ratio of -2.95 and a beta of 0.13. OmniAb, Inc. has a 1 year low of $1.22 and a 1 year high of $4.02.

Institutional Investors Weigh In On OmniAb

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC acquired a new stake in shares of OmniAb during the first quarter worth about $25,000. Osaic Holdings Inc. increased its position in OmniAb by 214.4% during the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock worth $25,000 after buying an additional 9,716 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of OmniAb by 92.5% in the third quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock valued at $35,000 after acquiring an additional 10,438 shares during the period. Cerity Partners LLC grew its position in shares of OmniAb by 111.5% during the second quarter. Cerity Partners LLC now owns 22,612 shares of the company’s stock worth $39,000 after acquiring an additional 11,919 shares during the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of OmniAb by 96.6% in the 4th quarter. SG Americas Securities LLC now owns 23,141 shares of the company’s stock valued at $43,000 after acquiring an additional 11,369 shares during the period. 72.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of OmniAb in a report on Monday, December 22nd. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, OmniAb has an average rating of “Moderate Buy” and a consensus target price of $6.67.

OmniAb Company Profile

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.